By Kate Kelland LONDON (Reuters) – A new hepatitis C vaccine from GlaxoSmithKline based on the same technology as an experimental Ebola shot being fast-tracked through human trials has shown promise in early clinical tests, prompting strong and broad immune responses. Researchers testing the vaccine — the first hepatitis C vaccine to reach second stage clinical trials — said their results in a group of 15 healthy human volunteers showed it was very safe and well tolerated, and generated immune responses of a strength never seen before in a vaccine against this disease. …
Source: https://in.news.yahoo.com/gsk-hepatitis-c-shot-shows-promise-bodes-well-191438067–finance.html